CN111448212A - 抗trem2抗体及其使用方法 - Google Patents
抗trem2抗体及其使用方法 Download PDFInfo
- Publication number
- CN111448212A CN111448212A CN201880069782.0A CN201880069782A CN111448212A CN 111448212 A CN111448212 A CN 111448212A CN 201880069782 A CN201880069782 A CN 201880069782A CN 111448212 A CN111448212 A CN 111448212A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- seq
- sequence
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558803P | 2017-09-14 | 2017-09-14 | |
| US62/558,803 | 2017-09-14 | ||
| US201762583379P | 2017-11-08 | 2017-11-08 | |
| US62/583,379 | 2017-11-08 | ||
| US201862621380P | 2018-01-24 | 2018-01-24 | |
| US62/621,380 | 2018-01-24 | ||
| PCT/US2018/051166 WO2019055841A1 (en) | 2017-09-14 | 2018-09-14 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111448212A true CN111448212A (zh) | 2020-07-24 |
Family
ID=63714159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880069782.0A Pending CN111448212A (zh) | 2017-09-14 | 2018-09-14 | 抗trem2抗体及其使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200277373A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3681909A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7403441B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111448212A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3075285A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019055841A1 (cg-RX-API-DMAC7.html) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112526143A (zh) * | 2020-12-03 | 2021-03-19 | 中山大学附属第五医院 | 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用 |
| CN114667295A (zh) * | 2019-11-22 | 2022-06-24 | 伊莱利利公司 | Trem2抗体及其用途 |
| CN117534569A (zh) * | 2023-11-23 | 2024-02-09 | 复旦大学附属华山医院 | S-9-pahsa在制备阿尔兹海默病及认知障碍疾病治疗药物中的用途 |
| CN117964768A (zh) * | 2024-04-02 | 2024-05-03 | 上海宏成药业有限公司 | 抗trem2抗体及其用途 |
| WO2024250809A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都优洛生物科技有限公司 | 抗trem2全人源抗体或其抗原结合片段及其应用 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201790342A1 (ru) | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| HUE062436T2 (hu) | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| CA3109763A1 (en) * | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| CA3120875A1 (en) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| CN110511240B (zh) * | 2019-08-27 | 2022-03-08 | 南京医科大学 | 一种髓细胞触发受体2的内源性配体及其应用 |
| CN115003699A (zh) | 2019-12-05 | 2022-09-02 | 艾利妥 | 抗trem2抗体的使用方法 |
| US20230265212A1 (en) * | 2019-12-19 | 2023-08-24 | Kevin S. EISENFRATS | Compositions and methods for oocyte-specific contraception |
| WO2021146256A1 (en) * | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| US11124567B2 (en) * | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CN115768794A (zh) | 2020-02-24 | 2023-03-07 | 艾利妥 | 抗trem2抗体的使用方法 |
| CA3172451A1 (en) | 2020-04-03 | 2021-10-07 | Robert Paul | Methods of use of anti-trem2 antibodies |
| CN111793131A (zh) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | 一种用于检测血清中pf4含量的抗体对及其用途 |
| CN116323667A (zh) * | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| CN114075284B (zh) * | 2020-08-17 | 2023-11-17 | 上海元宋生物技术有限公司 | Cd47结合分子及其用途 |
| WO2022045865A1 (ko) * | 2020-08-31 | 2022-03-03 | (주)메디톡스 | 항-vegf 육량체 항체, 및 이를 포함하는 조성물 |
| US20240102094A1 (en) * | 2020-12-03 | 2024-03-28 | Amgen Inc. | Trem2 agonist biomarkers and methods of use thereof |
| WO2022241082A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Agonists of trem2 |
| IL308804A (en) * | 2021-05-28 | 2024-01-01 | Vigil Neuroscience Inc | TREM2 agonistic biomarkers and methods of using them |
| CN115505041B (zh) * | 2021-06-22 | 2026-05-05 | 北京免疫方舟医药科技有限公司 | 抗EphA2抗体及其应用 |
| IL285416A (en) * | 2021-08-05 | 2023-03-01 | Yeda Res & Dev | Antibodies for cancer treatment |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| US20240392035A1 (en) * | 2021-08-25 | 2024-11-28 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| WO2023039612A1 (en) * | 2021-09-13 | 2023-03-16 | The Board Of Regents Of The University Of Texas System | Trem2 antigen binding proteins and uses thereof |
| MX2024010324A (es) | 2022-02-23 | 2024-08-30 | Alector Llc | Metodos de uso de anticuerpos anti-trem2. |
| EP4499695A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| EP4499693A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023215697A1 (en) * | 2022-05-05 | 2023-11-09 | Eli Lilly And Company | Multispecific binding molecules and methods of use thereof |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのtrem-2アゴニスト |
| US20240262929A1 (en) * | 2023-02-06 | 2024-08-08 | Ibio, Inc. | Anti-muc16 antibodies |
| AU2024320793A1 (en) | 2023-08-09 | 2026-03-12 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| AU2024323186A1 (en) | 2023-08-09 | 2026-01-15 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025046298A2 (en) * | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104520329A (zh) * | 2012-08-29 | 2015-04-15 | 霍夫曼-拉罗奇有限公司 | 血脑屏障穿梭体 |
| CN107106679A (zh) * | 2014-08-08 | 2017-08-29 | 艾利妥 | 抗trem2抗体及其使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002021141A2 (en) | 2000-09-06 | 2002-03-14 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
| CN102268094A (zh) | 2002-08-30 | 2011-12-07 | 比奥雷克西斯药物公司 | 被修饰的转铁蛋白抗体的融合蛋白 |
| DK2046826T3 (da) | 2006-07-24 | 2011-10-24 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteiner |
| TWI507525B (zh) * | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| JP7725185B2 (ja) | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
-
2018
- 2018-09-14 WO PCT/US2018/051166 patent/WO2019055841A1/en not_active Ceased
- 2018-09-14 US US16/646,536 patent/US20200277373A1/en not_active Abandoned
- 2018-09-14 EP EP18779998.6A patent/EP3681909A1/en active Pending
- 2018-09-14 CN CN201880069782.0A patent/CN111448212A/zh active Pending
- 2018-09-14 CA CA3075285A patent/CA3075285A1/en active Pending
- 2018-09-14 JP JP2020515175A patent/JP7403441B2/ja active Active
-
2023
- 2023-08-24 JP JP2023136384A patent/JP2023163183A/ja active Pending
-
2025
- 2025-07-04 JP JP2025113952A patent/JP2025133893A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104520329A (zh) * | 2012-08-29 | 2015-04-15 | 霍夫曼-拉罗奇有限公司 | 血脑屏障穿梭体 |
| CN107106679A (zh) * | 2014-08-08 | 2017-08-29 | 艾利妥 | 抗trem2抗体及其使用方法 |
Non-Patent Citations (1)
| Title |
|---|
| 周宓等: "跨血脑屏障药物转运的研究进展" * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114667295A (zh) * | 2019-11-22 | 2022-06-24 | 伊莱利利公司 | Trem2抗体及其用途 |
| CN114667295B (zh) * | 2019-11-22 | 2024-03-29 | 伊莱利利公司 | Trem2抗体及其用途 |
| CN112526143A (zh) * | 2020-12-03 | 2021-03-19 | 中山大学附属第五医院 | 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用 |
| WO2024250809A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都优洛生物科技有限公司 | 抗trem2全人源抗体或其抗原结合片段及其应用 |
| CN117534569A (zh) * | 2023-11-23 | 2024-02-09 | 复旦大学附属华山医院 | S-9-pahsa在制备阿尔兹海默病及认知障碍疾病治疗药物中的用途 |
| CN117964768A (zh) * | 2024-04-02 | 2024-05-03 | 上海宏成药业有限公司 | 抗trem2抗体及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025133893A (ja) | 2025-09-11 |
| WO2019055841A1 (en) | 2019-03-21 |
| JP2020534277A (ja) | 2020-11-26 |
| JP7403441B2 (ja) | 2023-12-22 |
| EP3681909A1 (en) | 2020-07-22 |
| US20200277373A1 (en) | 2020-09-03 |
| CA3075285A1 (en) | 2019-03-21 |
| JP2023163183A (ja) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7403441B2 (ja) | 抗trem2抗体及びその使用方法 | |
| US11124567B2 (en) | Anti-TREM2 antibodies and methods of use thereof | |
| US11370832B2 (en) | Anti-Tau antibodies and methods of use thereof | |
| AU2021208482B2 (en) | Anti-TREM2 antibodies and methods of use thereof | |
| JP7159185B2 (ja) | 抗phf-タウ抗体及びその使用 | |
| TWI879756B (zh) | 抗trem2抗體及其使用方法 | |
| JP2020168003A (ja) | 抗FcRn抗体 | |
| JP7362636B2 (ja) | 抗phf-タウ抗体及びその使用 | |
| WO2018237338A1 (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| CN112739422B (zh) | Cd200r激动剂抗体及其用途 | |
| WO2019094576A1 (en) | Bace-tau bispecific antibodies | |
| KR20230034367A (ko) | 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도 | |
| KR20220092859A (ko) | 항-cxcr2 항체 및 이의 용도 | |
| US20250215077A1 (en) | Monovalent anti-trem2 binding molecules and methods of use thereof | |
| HK40086025B (en) | Anti-human nr1 antibody derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |